Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out forZacks Investment Research · 3 days ago
PTC Therapeutics (NASDAQ:PTCT) Director Sells $149,025.00 in StockDefense World · 6 days ago
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026PRNewsWire · Oct 15, 2026
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 435 Shares of Company StockDefense World · Oct 8, 2026
Comparing PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN)Defense World · Oct 5, 2026
PTC Therapeutics (NASDAQ:PTCT) Shares Climb 4.7% – Here’s WhyDefense World · Sep 30, 2026PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | $0.24 | $0.92 | Beat |
| May 7, 2026 | -$0.45 | -$0.03 | Beat |
| Feb 19, 2026 | -$0.21 | -$1.67 | Miss |
| Nov 4, 2025 | -$1.19 | $0.20 | Beat |
| Aug 7, 2025 | -$1.07 | -$0.83 | Beat |
| May 6, 2025 | -$1.08 | $10.04 | Beat |